March 24, 2026
Nexsen (ASX:NXN) advances StrepSure® with FDA feedback confirming U.S. approval pathway
Nexsen advances StrepSure® toward U.S. market entry following FDA Pre Submission feedback that clarifies and de risks its regulatory pathway.